Sign in
Active, not recruitingPhase 3

A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

Key facts

Who runs it
Hoffmann-La Roche
Where
Altamonte Springs, Aurora, Dallas, Detroit, Iowa City, New York, Rochester, and San Francisco, United StatesSee the 8 sitesAlso in 10 other countries, 42 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
142 people enrolled
Started
25 Jun 2021
Expected to end
21 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Obinutuzumab
  • Tacrolimus
  • Methylprednisolone
  • Acetaminophen
  • Diphenhydramine
Record updated
1 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Diagnosis of primary membranous nephropathy (pMN) according to renal biopsy prior to or during screening
  • Screening urinary protein-to-creatinine ratio (UPCR) >= 5 g/g from 24-hour urine collection after best supportive care for >= 3 months prior to screening or screening UPCR >= 4 g/g after best supportive care for >= 6 months prior to screening
  • eGFR >= 40 mL/min/1.73m\^2 or qualified endogenous creatinine clearance >= 40 mL/min/1.73m\^2 based on 24-hour urine collection during screening
  • Other inclusion criteria may apply

Who cannot take part

  • Evidence of >= 50% reduction in proteinuria during the previous 6 months prior to randomization
  • Receipt of an excluded therapy, including any anti-CD20 therapy less than 9 months prior to or during screening; or cyclophosphamide, tacrolimus, or cyclosporin less than 6 months prior to or during screening
  • Major surgery requiring hospitalization within the 4 weeks prior to screening
  • Current active alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening
  • Intolerance or contraindication to study therapies
  • Severe renal impairment, including the need for dialysis or renal replacement therapy
  • Type 1 or 2 diabetes mellitus
  • Significant or uncontrolled medical disease which, in the investigator's opinion, would preclude participant participation
  • Known active infection of any kind or recent major episode of infection
  • Participants with a secondary cause of MN
  • Pregnancy or breastfeeding
  • Other exclusion criteria may apply

Where in United States

Also in 10 other countries, 42 sites

  • Accel Research Sites; Mid-Florida Kidney and Hypertension CareAltamonte Springs, United States
  • University of Colorado in Denver-Anschutz Medical CampusAurora, United States
  • Nephrotex Research GroupDallas, United States
  • Henry Ford HospitalDetroit, United States
  • University of IowaIowa City, United States
  • Columbia University Medical CenterNew York, United States
  • Mayo ClinicRochester, United States
  • Kaiser Permanente San Francisco Medical CenterSan Francisco, United States

About the trial

What the trial wants to find out

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

The 2 groups in the trial

  • Open Label Treatment: ObinutuzumabTreatment being tested

    Participants will be randomized at a 1:1 ratio to receive open-label treatment with obinutuzumab according to region and anti-phospholipase A2 receptor (PLA2R) autoantibody titer (using Euroimmun ELISA).

    Treatment: Obinutuzumab, Methylprednisolone, Acetaminophen, and Diphenhydramine

  • Open Label Treatment: TacrolimusExisting treatment, for comparison

    Participants will be randomized at a 1:1 ratio to receive open-label treatment with tacrolimus according to region and anti-PLA2R autoantibody titer (using Euroimmun ELISA).

    Treatment: Tacrolimus

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
Publications
Record updated
1 October 2026